Skip to main contentLast updated: 05-Nov-2026
Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Intestine Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
Cancer of the small bowel is rare, so no large trial has ever tested its treatment. The guidelines from the United States (NCCN) and Europe (ESMO) are expert agreement, not trial proof.
They are firm on four things. These are a complete operation with the nearby glands, a tissue test called MMR on every tumour, chemotherapy after surgery when glands are involved, and immunotherapy for some spread disease.
They are honest about what is unknown, such as chemotherapy for early stage disease and how to follow up. Those points are decided by a team and by you.
To see how these tumours are treated here, read our small bowel cancer treatment page. This post explains what the guidelines advise, where they are firm, and where they are not.
The disease is too rare for doctors to run large trials. So the guidelines borrow from bowel cancer of the colon, and they say so openly.
| Kind of advice | How firm it is | Example |
|---|---|---|
| Surgical and tissue-test principles | Firm, from surgical logic and case series | Remove the tumour completely; test every tumour for MMR |
| Borrowed from colon cancer | A reasonable default, not proven in the small bowel | Chemotherapy after surgery; the first-line drug pair |
| Open questions | Decided case by case | Chemotherapy for early stage disease; follow-up schedule |
When someone says “the guidelines say so”, ask which of these three it is. The answer tells you how much weight the advice can bear.
The American and European bodies agree on the core of care. If these steps are done well, most of the benefit that treatment can give is secured.
| Step | What is advised | In plain words |
|---|---|---|
| Operation | Remove the tumour with clear edges, plus the nearby glands in the fold of tissue that holds the bowel | The only treatment that can remove the disease for good |
| Gland count | Enough glands removed and examined | Too few glands makes the stage look lower than it is |
| MMR or MSI test | On every tumour | Shows who may respond to immunotherapy and who needs a family check |
| After surgery | Chemotherapy offered when glands carry cancer | Borrowed from colon cancer, direction agreed |
| Spread disease | A two-drug chemotherapy pair first | The usual starting point when the MMR test is normal |
| Spread disease with MMR change | Immunotherapy that releases the body’s defence cells | Often a strong and lasting response |
| Young or family history | Referral for gene testing and counselling | Protects the patient and relatives |
| Team | Plan the case in a tumour board | Needed because the disease is rare and complex |
If the guidelines had to fit on a card, it would hold four lines. Complete operation with enough glands. MMR test on every tumour. Chemotherapy when glands are involved. Immunotherapy when the MMR test shows a change in spread disease.
Our posts on tests and their order and on symptoms that get missed show how a case reaches this point.
One cheap test on the tumour tissue can change the whole plan. It is the firmest tissue-test advice in every guideline.
Ask for the result in writing. If it was not done, ask for it to be added to the tissue you already have.
The honest gaps matter as much as the firm advice. Here the answer depends on you, the report and the team.
| Question | State of the advice | How we decide |
|---|---|---|
| Chemotherapy after surgery for early stage disease | Benefit unknown; offered for risk signs such as a tear, a blood vessel finding, or too few glands | Weigh the risk signs against your fitness and the side effects |
| Which drugs, and for how long | Copied from colon cancer, not tested in the small bowel | Use the colon pattern and say clearly that it is borrowed |
| Tumours of the duodenum near the bile duct opening | Handled partly under separate pathways | Find the tumour’s cell type first, then choose the route |
| Targeted drugs for a changed gene | Testing is advised in spread disease; uses are still growing | Test, then discuss at the tumour board |
| Chemotherapy before surgery | Little evidence; a discussion item for large or borderline tumours | Individual decision at the tumour board |
| Follow-up after treatment | No schedule proven by a trial | A sensible plan borrowed from colon cancer |
| Removing a few spread spots | Allowed in selected cases without trial proof | Only for a fit person with limited spread |
The biggest gap is chemotherapy after surgery when no glands are involved. Nobody can promise a benefit there, and anyone who does is going beyond the evidence.
The direction travels well. Drug access, cost and the chance of gut tuberculosis change what is practical.
The guidelines in this post concern the common gland-forming cancer. Lymphoma and neuroendocrine tumours follow their own rules.
A good plan can show you each of these points. If one is missing, ask for it before treatment starts.
A missed point is not always a mistake, because there may be a reason. It should be written down and explained to you.
Yes. The American NCCN and the European ESMO both publish advice for the common gland-forming type. Because no large trial exists, both rest on expert agreement and on lessons from colon cancer.
They agree on five points. These are a complete operation with the nearby glands, an MMR test on every tumour, chemotherapy after surgery when glands are involved, a two-drug chemotherapy pair for spread disease, and immunotherapy when the MMR test shows a change.
This is the biggest open question. The guidelines offer it for risk signs rather than for everyone. The choice is made with you, weighing the findings against your fitness and the side effects.
It is a test on the tumour tissue that shows whether the tumour can repair its own DNA errors. A change predicts a good response to immunotherapy and may point to an inherited condition in the family.
Not in the same way. The guideline discussed here is for the gland-forming cancer. Lymphoma and neuroendocrine tumours, and GIST, each have their own advice and treatment.
No trial has proved one. Doctors use a sensible plan borrowed from colon cancer. Visits, blood tests and scans are spaced out over the years and adjusted to your stage.
Yes. The disease is rare and the choices are complex. So the guidelines advise planning each case with surgeons, cancer physicians and pathologists together.
For the full range of small bowel tumour care, start at the small bowel cancer treatment page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
Were you handed a plan for a small bowel tumour and told it "follows the guidelines", without hearing what that means? Dr Harsh Shah will go through your reports. He will show which parts of the plan are firm and which are judgement, and explain why. Call, or send a message on WhatsApp. Call +91-63555-64601 Ask on WhatsApp
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.